Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva’s generic Wellbutrin XL equivalence validated

Executive Summary

FDA reaffirms the therapeutic equivalence of Teva's extended-release bupropion tablets April 16 following a re-evaluation of the safety and efficacy for the antidepressant. FDA initiated the review of the generic version of GlaxoSmithKline's Wellbutrin XL (bupropion) after receiving 85 post-marketing reports in the first half of 2007. The majority of the reports involve loss of efficacy following a switch from the brand to generic product, which is manufactured by Impax. Other reports were for onset or worsening of side effects, consistent with the adverse effects in labeling. However, FDA concludes that Teva's 300 mg tablets, marketed as Budeprion XL, are bioequivalent and therapeutically equivalent to Wellbutrin XL, despite small differences in pharmacokinetic profiles. Impax is also approved for 100 mg, 150 mg and 200 mg dosages of extended-release bupropion. Other manufacturers of generic Wellbutrin XL include Sandoz, Anchen, Actavis and Watson

You may also be interested in...



EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments

While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.

COVID-19: US Acted To Beat Other Countries To Next 1.25M Doses Of Regeneron Cocktail

Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.

UsernamePublicRestriction

Register

LL029263

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel